- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- Resource Library
- Mental Health Disorders
- Agitation
- Anxiety Disorders
- Bipolar Disorder
- Cognition
- Depression
- Eating Disorders
- Personality Disorders
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Women’s Health
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Early Episode Psychosis
- Health Care Policy & Legislation
- Neuroscience
- Payer & Financing Models
- Quality Standards & Performance Measures
- Stigma
- Suicide Awareness
- Wellness
- Collections
- Featured
- Monthly Spotlight
- Psychopharmacology
- Learning Tracks
- Community Insights
- Community Podcast
- Disease Management & Support Tools
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Patient & Caregiver Resource Center
- PsychU Roleplay
- Psychiatric Scales
- PsychUSim
- Events
Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Current Guidelines & Unmet Needs In The Treatment Of Agitation Associated With Alzheimer’s Dementia
This is a Virtual Live Event for PsychU members in Connecticut, New Jersey, and New York City, NY.
Individualized and multimodal treatment plans are recommended for patients with Alzheimer’s disease and Agitation associated with Alzheimer’s Dementia (AAD). There is a need for better identification of AAD. There is also a need for approved pharmacological treatments that have proven and favorable benefit: risk profiles to reduce symptoms and ultimately improve burden to caregivers and healthcare.
In this discussion, current treatment guidelines, assess risk/benefit profile, and discuss unmet needs of AAD treatment will be reviewed.
Featuring
Jehan Marino, PharmD, BCPP (OPDC)
Clinical & Scientific Director
Alyssa Weers, PharmD (OPDC)
Clinical & Scientific Liaison
Speakers Alyssa Weers PharmD and Jehan Marino PharmD, BCPP are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Related Events
-
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
February 14 3:00 pm to 4:00 pm
Registration
Related Resources
-
PsychU Brochure 2023
Downloadable Resource January 31, 2023Download Brochure
-
Pharmacokinetics, Plasma Concentrations (Their) & Clinical Relevance
On-Demand Webinar January 26, 2023Pharmacokinetics refers to the study of how drugs are processed by the body. These processes play an important role in mental health treatments, and can vary due to several factors,…
-
The Holidays – A Time For Silver, Gold, and… The Blues?
Podcast January 17, 2023Listen to Amica Simmons-Yon, PharmD, PhD and Alyssa Peckham, PharmD, BCPP as they spill the tea on The Holiday Blues with special guest, Bennett Doughty, PharmD, BCPS, BCPP. During this…
Stay Connected: